$JNJ 2Q operational sales -9.0% driven by impact of medical procedure deferrals on med devices unit (-32.5%). Pharma sales up (3.9%) while consumer health down marginally (-3.4%). EPS 17c above consensus. Shares +0.14% pre-mkt https://t.co/kkl98wrtu8